Jeff Albers and Kate Haviland (Brad Bahner Photography/PR Newswire)
Blueprint's longtime CEO prepares to step down as biotech revels in new Ayvakit launch, pipeline expansion
After a busy 2021 brought Blueprint Medicines its fourth FDA approval, the company is kicking off the new year with plans to shake up its …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
